AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7028085 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous timolol and epinephrine treatment
Number of subjects: 16
Study 7028085 — intervention group
Group type: COMPARATOR
Intervention: Timolol followed by epinephrine
Number of subjects: 16
Study 31674920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivibot chatbot (experimental group)
Number of subjects: 45
Study 31674920 — intervention group
Group type: COMPARATOR
Intervention: Daily emotion ratings (control group)
Number of subjects: 45
Study 28765638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction using laser projective point and projection invariant from five points on a 2D target
Number of subjects: 0
Study 28765638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction approach
Number of subjects: 0
Study 26154926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate (FPC) administered via dialysate (2 μmol/l of iron)
Number of subjects: 103
Study 26154926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard dialysate)
Number of subjects: 103
Study 26154926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate (FPC) administered via dialysate
Number of subjects: 103
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Food basket with health and nutrition education
Number of subjects: 3010
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Food basket without health and nutrition education
Number of subjects: 3010
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash with health and nutrition education
Number of subjects: 3010
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash without health and nutrition education
Number of subjects: 3010
Study 23343672 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3010
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Food basket group (obese women)
Number of subjects: 3010
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash group (obese women)
Number of subjects: 3010
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Food basket group (BMI 25-30 kg/m2)
Number of subjects: 3010
Study 23343672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash group (BMI 25-30 kg/m2)
Number of subjects: 3010
Study 21084403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin treatment (IIT) for 24 hours targeting glycemia less than 110 mg/dl
Number of subjects: 70
Study 21084403 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) with regular insulin if glycemia was greater than 200 mg/dl
Number of subjects: 70
Study 19179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer compression system
Number of subjects: 112
Study 19179971 — intervention group
Group type: COMPARATOR
Intervention: Four-layer compression system
Number of subjects: 112
Study 19179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with simultaneous insufficiency of two venous systems (superficial and deep)
Number of subjects: 112
Study 19179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with insufficiency of deep, superficial and perforating venous system
Number of subjects: 112
Study 19179971 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization on the back calf region
Number of subjects: 112
Study 17289894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m2 (weekly)
Number of subjects: 39
Study 17289894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (single doses of 250-500 mg/m2)
Number of subjects: 39
Study 17289894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (various single doses: 50, 100, 250, 400, 500 mg/m2)
Number of subjects: 39
Study 17289894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (250 mg/m2)
Number of subjects: 39
Study 15498524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylglycine (400 mg daily for 28 days)
Number of subjects: 7
Study 15498524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 28 days)
Number of subjects: 7
Study 14563654 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day orally)
Number of subjects: 48
Study 14563654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10614805 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural chest pain
Number of subjects: 0
Study 10614805 — intervention group
Group type: COMPARATOR
Intervention: Return to catheterization laboratory
Number of subjects: 0
Study 10614805 — intervention group
Group type: COMPARATOR
Intervention: Late postprocedural pain
Number of subjects: 0
Study 8532482 — intervention group
Group type: EXPERIMENTAL
Intervention: Faking Good
Number of subjects: 384
Study 8532482 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher
Number of subjects: 384
Study 8532482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal Teacher
Number of subjects: 384
Study 8532482 — intervention group
Group type: COMPARATOR
Intervention: Control (standard directions)
Number of subjects: 384
Study 1827102 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 120
Study 1827102 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 120
Study 6453571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar flexion exercise
Number of subjects: 28
Study 6453571 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 28
Study 6453571 — intervention group
Group type: COMPARATOR
Intervention: Home care
Number of subjects: 28
Study 30618197 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-3280
Number of subjects: 0
Study 30054895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2000-500 mg every 8 hours
Number of subjects: 42
Study 30054895 — intervention group
Group type: EXPERIMENTAL
Intervention: Avibactam 2000-500 mg every 8 hours
Number of subjects: 42
Study 26757276 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose intramuscular (i.m.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Number of subjects: 1047
Study 26757276 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose intravenous (i.v.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Number of subjects: 1047
Study 26757276 — intervention group
Group type: COMPARATOR
Intervention: Five-dose intramuscular (i.m.) artesunate regimen (2.4 mg/kg at 0, 12, 24, 48, and 72 hours)
Number of subjects: 1047
Study 26757276 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed anemia (post hoc analysis)
Number of subjects: 1047
Study 24216034 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 800/100 mg once daily monotherapy
Number of subjects: 30
Study 24216034 — intervention group
Group type: COMPARATOR
Intervention: darunavir/ritonavir 800/100 mg once daily + two NRTIs
Number of subjects: 30
Study 24216034 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group
Number of subjects: 30
Study 22278424 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline monotherapy (0.5 mg once daily for 18 weeks)
Number of subjects: 24
Study 22278424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cabergoline and pegvisomant (10 mg daily for 12 weeks)
Number of subjects: 24
Study 22278424 — intervention group
Group type: COMPARATOR
Intervention: Pegvisomant (10 mg daily after cabergoline withdrawal for 12 weeks)
Number of subjects: 24
Study 20634277 — intervention group
Group type: EXPERIMENTAL
Intervention: Arithmetic learning condition 1
Number of subjects: 70
Study 20634277 — intervention group
Group type: EXPERIMENTAL
Intervention: Arithmetic learning condition 2
Number of subjects: 70
Study 20634277 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training improvements
Number of subjects: 70
Study 17694391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette Guerin (BCG)
Number of subjects: 0
Study 17694391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15774238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing vitamin E, selenium, vitamin C, and coenzyme Q10
Number of subjects: 80
Study 15774238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12042275 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg/day in two divided doses for 4 weeks)
Number of subjects: 313
Study 12042275 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 313
Study 9801994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid plus heparin (250 ml 10% Intralipid plus 5000 U heparin)
Number of subjects: 14
Study 9801994 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, orally, at 0 min and at 210 min)
Number of subjects: 14
Study 9801994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7625469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 80 mg/day)
Number of subjects: 23
Study 7625469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31938726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) using active-play video games (i.e., Xbox Kinect) and traditional cardiovascular exercise equipment
Number of subjects: 200
Study 31938726 — intervention group
Group type: COMPARATOR
Intervention: Stretching-and-toning (ST) control intervention
Number of subjects: 200
Study 30037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-based regimen (paclitaxel plus trastuzumab with or without lapatinib)
Number of subjects: 137
Study 30037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated RNA and DNA models
Number of subjects: 137
Study 30037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Models using RNA only
Number of subjects: 137
Study 30037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplatform models including gene signatures, clinical features, and DNA information
Number of subjects: 137
Study 30037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic DNA alterations (mutation, CNAs), tumor molecular subtype (HER2E, Luminal), and microenvironment (immune cells)
Number of subjects: 137
Study 26474861 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin–tazobactam (CI)
Number of subjects: 78
Study 26474861 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin–tazobactam (II)
Number of subjects: 78
Study 24909499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid (200 mg once daily for 6 days)
Number of subjects: 666
Study 24909499 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg twice daily for 10 days)
Number of subjects: 666
Study 24909499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid
Number of subjects: 666
Study 24909499 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 666
Study 23140598 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach (Group 1)
Number of subjects: 62
Study 23140598 — intervention group
Group type: COMPARATOR
Intervention: Anterior approach (Group 2)
Number of subjects: 62
Study 19942995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuous rachidian and peridural analgesia (CRPA)
Number of subjects: 128
Study 19942995 — intervention group
Group type: COMPARATOR
Intervention: Continuous peridural analgesia (CPA)
Number of subjects: 128
Study 19942995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 128
Study 17893311 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 1162
Study 17893311 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 1162
Study 17893311 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1162
Study 14722206 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIL 284 25 mg
Number of subjects: 26
Study 14722206 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIL 284 150 mg
Number of subjects: 26
Study 14722206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11280672 — intervention group
Group type: EXPERIMENTAL
Intervention: Automode (AM)
Number of subjects: 40
Study 11280672 — intervention group
Group type: COMPARATOR
Intervention: synchronised intermittent mandatory ventilation (SIMV)
Number of subjects: 40
Study 9459192 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg p.o. once daily
Number of subjects: 30
Study 9459192 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg p.o. once daily
Number of subjects: 30
Study 9459192 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (both doses combined)
Number of subjects: 30
Study 9459192 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (both doses)
Number of subjects: 30
Study 7943584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hepatic ultrasonography (IOUS)
Number of subjects: 62
Study 3540835 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy (bovine surfactant, surfactant TA)
Number of subjects: 41
Study 3540835 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study 31896118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 IU)
Number of subjects: 123
Study 31896118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 30409109 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP
Number of subjects: 13
Study 30409109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26473443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (1 hour, 2 times a week)
Number of subjects: 47
Study 26473443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 47
Study 26473443 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued daily activities)
Number of subjects: 47
Study 26215666 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination of eligible adults with single dose vaccination
Number of subjects: 0
Study 26215666 — intervention group
Group type: COMPARATOR
Intervention: Vaccination delayed by 21 days
Number of subjects: 0
Study 23539885 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified human menopausal gonadotropin (HP-hMG)
Number of subjects: 173
Study 23539885 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle-stimulating hormone (rhFSH)
Number of subjects: 173
Study 23539885 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal inserts (PVI)
Number of subjects: 173
Study 23539885 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of progesterone in oil (PIO)
Number of subjects: 173
Study 21106086 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily
Number of subjects: 480
Study 21106086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 18808279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotized participants responding to unanswerable and misleading questions
Number of subjects: 0
Study 18808279 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hypnotized participants responding to unanswerable and misleading questions
Number of subjects: 0
Study 18808279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotized participants responding to answerable questions
Number of subjects: 0
Study 18808279 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hypnotized participants responding to answerable questions
Number of subjects: 0
Study 18808279 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings regarding DK responses
Number of subjects: 0
Study 18808279 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings regarding unanswerable questions
Number of subjects: 0
Study 15986229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg body weight Roc (Roc group)
Number of subjects: 120
Study 15986229 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg/kg succinylcholine (Sux; control group)
Number of subjects: 120
Study 12552184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg intravenous
Number of subjects: 135
Study 12552184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenous
Number of subjects: 135
Study 12552184 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0.625 mg intravenous and dexamethasone 4 mg intravenous (control)
Number of subjects: 135
Study 10540047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium 5000 units s.c. injection administered twice daily for 12 weeks
Number of subjects: 12
Study 8911400 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (rt-PA)
Number of subjects: 237
Study 8911400 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (UK)
Number of subjects: 237
Study 8911400 — intervention group
Group type: COMPARATOR
Intervention: Surgical revascularization
Number of subjects: 237
Study 1989365 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) by mask
Number of subjects: 43
Study 1989365 — intervention group
Group type: COMPARATOR
Intervention: Control (self‐administered chest physiotherapy alone)
Number of subjects: 43
Study 6815974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 50 mg (another 50 mg 4 h later)
Number of subjects: 40
Study 6815974 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 40
Study 6815974 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine
Number of subjects: 40
Study 6815974 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 29703335 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM-P (intravenous gemcitabine 1000 mg/m2 on days 1, 8, and 15, cisplatin 100 mg/m2 on day 15, and oral or intravenous methylprednisolone 1000 mg on days 1-5) every 28 days for four cycles
Number of subjects: 87
Study 29703335 — intervention group
Group type: COMPARATOR
Intervention: CHOP (intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2 mg] on day 1, and oral prednisolone 100 mg on days 1-5) every 21 days for six cycles
Number of subjects: 87
Study 29703335 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM-P
Number of subjects: 87
Study 29703335 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 87
Study 26540238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Telehealth (MTH) intervention
Number of subjects: 81
Study 25440807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation
Number of subjects: 50
Study 25440807 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation (control)
Number of subjects: 50
Study 22229650 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol and remifentanil
Number of subjects: 50
Study 22229650 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anaesthesia with sevoflurane and fentanyl
Number of subjects: 50
Study 20550223 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 626
Study 20550223 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus + IFNalpha
Number of subjects: 626
Study 18090045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (800 mg)
Number of subjects: 0
Study 18090045 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (1200 mg)
Number of subjects: 0
Study 18090045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15054216 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiles in peripheral blood mononuclear cells of autoimmune individuals and unaffected first‐degree relatives
Number of subjects: 0
Study 15054216 — intervention group
Group type: COMPARATOR
Intervention: Gene expression profiles in normal individuals after immunization
Number of subjects: 0
Study 11697387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment for unborn children
Number of subjects: 0
Study 11697387 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 9558288 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha2b (6 megaunits/m2 thrice weekly for 24 weeks)
Number of subjects: 144
Study 9558288 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 144
Study 8092901 — intervention group
Group type: COMPARATOR
Intervention: H2 blocker (continuous infusion of ranitidine at 0.25 mg/kg/hr after a loading dose of 0.5 mg/kg) plus antacids
Number of subjects: 98
Study 8092901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g every 6 hours via nasogastric tube)
Number of subjects: 98
Study 3287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 209
Study 3287907 — intervention group
Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 209
Study 3287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 209
Study 3287907 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 648 mg
Number of subjects: 209
Study 4343678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate and oxymetholone
Number of subjects: 0
Study 4343678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31954417 — intervention group
Group type: EXPERIMENTAL
Intervention: Generating positive arguments
Number of subjects: 0
Study 31954417 — intervention group
Group type: COMPARATOR
Intervention: Generating negative arguments
Number of subjects: 0
Study 30326880 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular partners
Number of subjects: 1057
Study 30326880 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual partners
Number of subjects: 1057
Study 30326880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of partners
Number of subjects: 1057
Study 26846550 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 mg)
Number of subjects: 27
Study 26846550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24705757 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw vegetable meals
Number of subjects: 153
Study 24705757 — intervention group
Group type: COMPARATOR
Intervention: Boiled vegetable meals
Number of subjects: 153